AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32510046
Drug: Low load
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low load treatment
Trial: 32511251
Drug: Intravenous ferric
RxNorm normalized name: Ferric Oxide
DrugBank: Ferric oxide (DB11576)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ferric carboxymaltose (1,000 mg) infusion on the first day of treatment
Trial: 32511251
Drug: Intravenous ferric
RxNorm normalized name: Ferric Oxide
DrugBank: Ferric oxide (DB11576)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ferric carboxymaltose (1,000 mg) infusion
Trial: 32511534
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of Nitric Oxide (NO)
Trial: 32511695
Drug: Oral capsulized
RxNorm normalized name: Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsulized fecal microbiota transplantation (FMT) for 2 days
Trial: 32511695
Drug: Post-FMT antibiotics
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-FMT antibiotics
Trial: 32511695
Drug: CPE carriers
RxNorm normalized name: Valiant Barrier
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPE carriers who failed treatment
Trial: 32512291
Drug: Valsartan (titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan (titrated to blood pressure up to a maximum of 160 mg bid)
Trial: 32513113
Drug: VPIA analgesic
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VPIA analgesic infusion pump
Trial: 32513801
Drug: Meropenem 40
RxNorm normalized name: Meropenem
DrugBank: Meropenem (DB00760)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Meropenem 40 mg/kg/dose every 8 hours as a 4-hour infusion
Trial: 32513801
Drug: Meropenem 110
RxNorm normalized name: Meropenem
DrugBank: Meropenem (DB00760)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Meropenem 110 mg/kg/day as a continuous infusion
Trial: 32514450
Drug: Sodium-glucose cotransporter
RxNorm normalized name: glucose / sodium chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium-glucose cotransporter 2 (SGLT2) inhibitors for 12 weeks
Trial: 32514886
Drug: 5-ALA (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-ALA (200 mg/kg intraperitoneal)
Trial: 32514886
Drug: SWIG (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SWIG (5 mg/kg intravenous)
Trial: 32514886
Drug: 5-ALA (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-ALA (20 mg/kg oral)
Trial: 32514886
Drug: SWIG (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SWIG (2.5 mg/kg intravenous)
Trial: 32515349
Drug: 'agonist-only' Activin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 'agonist-only' Activin A muteins that activate ACVR1B but cannot form the non-signaling complex (NSC) with ACVR1
Trial: 32516377
Drug: Pembrolizumab (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab (200 mg, 3 courses)
Trial: 32517405
Drug: Erector spinae
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erector spinae plane (ESP) block with 20 mL of 0.5% plain bupivacaine
Trial: 32517690
Drug: Glucocorticoids and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucocorticoids and hormone replacement
Trial: 32518208
Drug: hs-cTnT >50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hs-cTnT >50 ng/L
Trial: 32518208
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of hs-cTnT >50 ng/L and a second independent predictor
Trial: 32518419
Drug: Ruxolitinib (Rux)
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ruxolitinib (Rux) - Janus Kinase 1/2 inhibitor, administered with efficacy/toxicity guided step up dosing up to 14 days
Trial: 32518518
Drug: Nurse-led, person-centred,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nurse-led, person-centred, health-promoting follow-up programme (includes two telephone calls and three visits to a vascular nurse in the first year after surgical treatment)
Trial: 32518518
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care (visit to a vascular surgeon 4-8 weeks after surgery and a visit to the outpatient clinic 1 year after surgical treatment)
Trial: 32518597
Drug: Steroidal aromatase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroidal aromatase inhibitors
Trial: 32518597
Drug: Nonsteroidal aromatase
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonsteroidal aromatase inhibitors
Trial: 32518833
Drug: Regular cohort
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular cohort (three initial monthly IVT-AFL injections and ≥6 injections)
Trial: 32518833
Drug: Irregular cohort
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irregular cohort with three initial monthly injections
Trial: 32518833
Drug: Irregular cohort
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irregular cohort without three initial monthly injections
Trial: 32518833
Drug: Regular cohort
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular cohort vs irregular cohort without three initial monthly injections
Trial: 32518833
Drug: Irregular cohort
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irregular cohort with three initial monthly injections vs irregular cohort without three initial monthly injections
Trial: 32518861
Drug: Tolvaptan modified-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolvaptan modified-release (MR) 120 mg
Trial: 32518861
Drug: Tolvaptan immediate-release
RxNorm normalized name: Tolvaptan
DrugBank: Tolvaptan (DB06212)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tolvaptan immediate-release (IR) 90+30 mg
Trial: 32518861
Drug: Tolvaptan MR
RxNorm normalized name: Tolvaptan
DrugBank: Tolvaptan (DB06212)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tolvaptan MR (various doses 20 to 120 mg)
Trial: 32518862
Drug: Tolvaptan MR
RxNorm normalized name: Tolvaptan
DrugBank: Tolvaptan (DB06212)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tolvaptan MR 50 mg once daily
Trial: 32518862
Drug: Tolvaptan MR
RxNorm normalized name: Tolvaptan
DrugBank: Tolvaptan (DB06212)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tolvaptan MR 80 mg once daily
Trial: 32518862
Drug: Tolvaptan IR
RxNorm normalized name: Tolvaptan
DrugBank: Tolvaptan (DB06212)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tolvaptan IR 60/30 mg daily split dose
Trial: 32518891
Drug: Seasonal trivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seasonal trivalent split, inactivated influenza vaccine (TIV) 0.5 ml (15 µg of hemagglutinin per strain)
Trial: 32521310
Drug: Camidanlumab tesirine
RxNorm normalized name: Camidanlumab tesirine
DrugBank: Camidanlumab tesirine (DB16411)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camidanlumab tesirine at 3-92 μg/kg Q3W (n = 26) or 30 or 37.5 μg/kg QW (n = 9)
Trial: 32521607
Drug: B cell
RxNorm normalized name: B cell antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B cell targeted therapies
Trial: 32522280
Drug: Iodine-to-creatinine ratio
RxNorm normalized name: Creatinine
DrugBank: Creatinine (DB11846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iodine-to-creatinine ratio (I:Cr) at 25th percentile (59 μg/g)
Trial: 32522280
Drug: Iodine-to-creatinine ratio
RxNorm normalized name: Creatinine
DrugBank: Creatinine (DB11846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iodine-to-creatinine ratio (I:Cr) at 75th percentile (121 μg/g)
Trial: 32522846
Drug: ACE2 activity
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE2 activity enhancement drugs
Trial: 32522846
Drug: RAS blockers
RxNorm normalized name: RAS
DrugBank: Rasagiline (DB01367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: RAS blockers (ACE inhibitors and angiotensin II receptor blockers)
Trial: 32523090
Drug: E7449 (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E7449 (600 mg, maximum-tolerated dose)
Trial: 32523090
Drug: E7449 (50-800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E7449 (50-800 mg doses)
Trial: 32523090
Drug: E7449 (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E7449 (800 mg)
Trial: 32523090
Drug: E7449 (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E7449 (600 mg)
Trial: 32523648
Drug: Metformin alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin alone (Arm A)
Trial: 32523648
Drug: Metformin with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin with rapamycin (Arm B)
Trial: 32524053
Drug: Perampanel monotherapy
RxNorm normalized name: Perampanel
DrugBank: Perampanel (DB08883)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Perampanel monotherapy at 4 mg/d during the 26-week Maintenance Period
Trial: 32524053
Drug: Perampanel monotherapy
RxNorm normalized name: Perampanel
DrugBank: Perampanel (DB08883)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Perampanel monotherapy at 4 or 8 mg/d during the 26-week Maintenance Period
Trial: 32524053
Drug: Perampanel monotherapy
RxNorm normalized name: Perampanel
DrugBank: Perampanel (DB08883)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Perampanel monotherapy at 4 mg/d during Maintenance
Trial: 32524053
Drug: Perampanel monotherapy
RxNorm normalized name: Perampanel
DrugBank: Perampanel (DB08883)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Perampanel monotherapy at 4 or 8 mg/d during Maintenance
Trial: 32524319
Drug: ABBV-176 (2.7-109.35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABBV-176 (2.7-109.35 μg/kg)
Trial: 32525018
Drug: Days on
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Days on renal replacement therapy
Trial: 32526533
Drug: Warfarin or
RxNorm normalized name: warfarin Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin or DOACs
Trial: 32527643
Drug: Autologous anti-EGFR
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous anti-EGFR chimeric antigen receptor-modified T (CAR T-EGFR) cells, median dose of CAR T cells: 3.48 × 10^6 cells, administered in one to three cycles within 6 months.
Trial: 32528286
Drug: Olanzapine treatment
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olanzapine treatment for 12 weeks
Trial: 32528389
Drug: Dog-assisted therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dog-assisted therapy (DAT)
Trial: 32528722
Drug: Optimized APD
RxNorm normalized name: APD-209
DrugBank: APD-209 (DB18759)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimized APD (7 × 2 L 2.27% + 5 × 2 L 0.1% over 8 h)
Trial: 32528722
Drug: Standard APD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard APD (6 × 2 L 1.36% over 9 h)
Trial: 32529175
Drug: Doxycycline for
RxNorm normalized name: Doxycycline for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline for 1 year along with chemotherapy
Trial: 32529495
Drug: Certolizumab pegol
RxNorm normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Certolizumab pegol (CZP) 400 mg loading dose at weeks 0, 2, and 4, followed by 200 mg every 2 weeks up to week 48
Trial: 32530764
Drug: Ivosidenib (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivosidenib (500 mg once per day)
Trial: 32531990
Drug: Conventional disease-modifying
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional disease-modifying anti-rheumatic drug (cDMARD) therapy
Trial: 32532097
Drug: H7N9 live
RxNorm normalized name: Typhoid Vaccine Live
DrugBank: Typhoid Vaccine Live (DB11050)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H7N9 live attenuated influenza vaccine (LAIV) administered intranasally, two doses.
Trial: 32532097
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered intranasally, two doses.
Trial: 32532225
Drug: Two-way messaging
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-way messaging therapy
Trial: 32532234
Drug: RTS,S/AS01 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RTS,S/AS01 vaccine (four-dose series: primary three doses followed by a fourth dose approximately 18 months later)
Trial: 32532234
Drug: RTS,S/AS01 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RTS,S/AS01 vaccine (four-dose series)
Trial: 32536573
Drug: Magnetic resonance-guided
RxNorm normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Magnetic resonance-guided radiation therapy (MRgRT)
Trial: 32536979
Drug: YYB101 (0.3,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YYB101 (0.3, 1, 3, 5, 10, 20, 30 mg/kg) administered intravenously once every 4 weeks for 1 month, then once every 2 weeks until disease progression or intolerable toxicity
Trial: 32536979
Drug: YYB101 (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YYB101 (20 mg/kg)
Trial: 32536984
Drug: Stepwise tapering
RxNorm normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Stepwise tapering of rhTNFR:Fc
Trial: 32536984
Drug: Delayed tapering
RxNorm normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Delayed tapering of rhTNFR:Fc
Trial: 32536984
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of rhTNFR:Fc
Trial: 32536984
Drug: rhTNFR:Fc 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhTNFR:Fc 25 mg monthly
Trial: 32538690
Drug: Pazopanib (dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazopanib (dosage and duration not available)
Trial: 32539744
Drug: Intravitreal injections
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injections of 0.5 mg ranibizumab under '1 + PRN' regimen
Trial: 32539794
Drug: 2.7 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.7 g/day of DHA
Trial: 32539794
Drug: 2.7 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.7 g/day of EPA
Trial: 32539794
Drug: 3 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g/day of corn oil (control)
Trial: 32540647
Drug: Continuous motion
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous motion monitoring based localization (Calypso) with initial localization, CBCT, pre-treatment motion correction by kV-imaging, and gating during irradiation (strategy A)
Trial: 32540647
Drug: Non-gated treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-gated treatments (strategy B)
Trial: 32540838
Drug: Tele-Exercise and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tele-Exercise and Multiple Sclerosis (TEAMS) intervention, 12-week complementary and alternative medicine (CAM) intervention with 20 sessions of synchronous training sessions of dual tasking, yoga, and Pilates exercises.
Trial: 32540858
Drug: Tislelizumab 0.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tislelizumab 0.5, 2, 5 or 10 mg/kg every 2 weeks; 2 or 5 mg/kg every 2 or 3 weeks; or 200 mg every 3 weeks (Phase IA)
Trial: 32540858
Drug: Tislelizumab 5
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tislelizumab 5 mg/kg every 3 weeks (Phase IB)
Trial: 32540858
Drug: Tislelizumab (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tislelizumab (all doses)
Trial: 32541292
Drug: Liposomal bupivacaine
RxNorm normalized name: bupivacaine liposome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal bupivacaine 1.3% (266 mg, 20 mL) and bupivacaine hydrochloride 0.25% (52 mg, 20 mL)
Trial: 32542466
Drug: Darifenacin 15
RxNorm normalized name: darifenacin 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Darifenacin 15 mg daily for 8 weeks
Trial: 32542468
Drug: Flortaucipir PET
RxNorm normalized name: Flortaucipir
DrugBank: Flortaucipir (DB15033)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flortaucipir PET (injection of ~370 mBq flortaucipir, 20-min PET scan starting 80 min post-injection)
Trial: 32542577
Drug: Antibiotic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic therapy initiated prior to sampling
Trial: 32542577
Drug: No prior
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No prior antibiotic exposure
Trial: 32542873
Drug: Current use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current use of antidepressants
Trial: 32542873
Drug: Imipramine-type antidepressants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine-type antidepressants
Trial: 32542873
Drug: Other or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other or mixed antidepressants
Trial: 32544297
Drug: N8-GP prophylaxis
RxNorm normalized name: N8-GP
DrugBank: Turoctocog alfa pegol (DB14738)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: N8-GP prophylaxis 75 IU/kg once weekly (Q7D)
Trial: 32544297
Drug: N8-GP (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N8-GP (all treatment arms)
Trial: 32545856
Drug: ILTHPI (Intraluminal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ILTHPI (Intraluminal Therapy for H. pylori Infection)
Trial: 32546071
Drug: Blinatumomab (9-28-112
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blinatumomab (9-28-112 μg/day) in a 70-day cycle 1 and an optional 28-day cycle 2
Trial: 32546071
Drug: Blinatumomab (9-28-112
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blinatumomab (9-28-112 μg/day)
Trial: 32546636
Drug: Incomplete aneurysm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Incomplete aneurysm occlusion after initial treatment
Trial: 32546636
Drug: Complete aneurysm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complete aneurysm occlusion after initial treatment
Trial: 32547188
Drug: Nanosomal docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nanosomal docetaxel lipid suspension (NDLS) chemotherapy (75-100 mg/m2)
Trial: 32547188
Drug: Nanosomal docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nanosomal docetaxel lipid suspension (NDLS) chemotherapy
Trial: 32547496
Drug: Preparation protocols
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preparation protocols
Trial: 32550738
Drug: Analgesic (Lidocaine
RxNorm normalized name: Workvie Roll On Analgesic (lidocaine HCl 4 % / menthol 1 % ) Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Analgesic (Lidocaine hydrochloride 40 mg plus adrenaline 0.025 mg) with tenaculum replacement
Trial: 32550738
Drug: Analgesic (Lidocaine
RxNorm normalized name: Workvie Roll On Analgesic (lidocaine HCl 4 % / menthol 1 % ) Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Analgesic (Lidocaine hydrochloride 40 mg plus adrenaline 0.025 mg) without tenaculum replacement
Trial: 32550738
Drug: No analgesic
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No analgesic with tenaculum replacement
Trial: 32550738
Drug: No analgesic
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No analgesic without tenaculum replacement
Trial: 32551439
Drug: Cap-assisted endoscopic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cap-assisted endoscopic sclerotherapy with long injection needle
Trial: 32551439
Drug: Cap-assisted endoscopic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cap-assisted endoscopic sclerotherapy with short injection needle
Trial: 32551797
Drug: Okada Purifying
RxNorm normalized name: RAYON,PURIFIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Okada Purifying Therapy
Trial: 32552266
Drug: Canakinumab 4
RxNorm normalized name: Canakinumab
DrugBank: Canakinumab (DB06168)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Canakinumab 4 mg/kg every 4 weeks for ≤48 weeks
Trial: 32552278
Drug: Lack of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lack of health care provider HPV vaccine recommendation
Trial: 32552278
Drug: Perceived lack
RxNorm normalized name: allogeneic CRISPR/Cas9 genome-edited hematopoietic stem and progenitor cell (HSPC) therapy product lacking the CD33 protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perceived lack of insurance coverage for the HPV vaccine
Trial: 32552299
Drug: Doll therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doll therapy
Trial: 34051177
Drug: Pembrolizumab 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 200 mg intravenously every 3 weeks for up to 24 months
Trial: 32553149
Drug: Ozanimod 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ozanimod 1.0 mg oral capsule daily for 12 weeks (after 7-day dose escalation)
Trial: 32554315
Drug: nab-paclitaxel monotherapy
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: nab-paclitaxel monotherapy (240 mg/m)
Trial: 32554609
Drug: E7046 (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E7046 (125 mg)
Trial: 32554609
Drug: E7046 (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E7046 (250 mg)
Trial: 32554609
Drug: E7046 (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E7046 (500 mg)
Trial: 32554609
Drug: E7046 (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E7046 (750 mg)
Trial: 32554609
Drug: E7046 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E7046 (all doses)